Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05411848
Other study ID # 2KCAL2022
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 17, 2022
Est. completion date December 15, 2023

Study information

Verified date February 2024
Source Nutricia UK Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to investigate the effects of a plant-based, high energy, high protein tube feed with and without inclusion of fibre on gastrointestinal tolerance in adult patients who require nutritional support via enteral tube feeding over a 28-day period, followed by a 12-month follow-up. Secondary aims are to determine the effects on compliance, acceptability, anthropometry, nutrient intake, and physical function. This is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period and a 1-year follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date December 15, 2023
Est. primary completion date December 15, 2023
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Male or female - =16 years of age - Using or requiring an enteral tube feed in the community as part of nutritional management plan - Expected to receive at least 1000kcal/day (one bottle) from one of the study products Exclusion Criteria: - Receiving parenteral nutrition - Patients with major hepatic dysfunction (i.e., decompensated liver disease) - Patients with major renal dysfunction (i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)) - Patients receiving inpatient care - Known pregnancy or lactation - Participation in other clinical intervention studies within 1 month of this study - Allergy to any study product ingredients - Investigator concern regarding ability or willingness of patient to comply with the study requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
2kcal HP PlantBased
Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.

Locations

Country Name City State
United Kingdom Nutricia Ltd. Trowbridge Wiltshire

Sponsors (1)

Lead Sponsor Collaborator
Nutricia UK Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in gastrointestinal tolerance A standardised gastrointestinal (GI) tolerance questionnaire to capture perceived severity (none, mild, moderate or severe) of common gastrointestinal symptoms (diarrhoea, constipation, bloating, abdominal discomfort, vomiting and nausea). Change from baseline (Day 1) to end of intervention (7-28 days)
Primary Change in gastrointestinal tolerance A standardised gastrointestinal (GI) tolerance questionnaire to capture perceived severity Change from baseline (Day 1) to end of follow-up (12 months)
Secondary Acceptability Acceptability (e.g., liking, ease of use, preference) will be assessed by a questionnaire. Questions will be rated on a 7-point Likert scale. Baseline to end of intervention (7-28 days) and end of follow-up (12 months)
Secondary Compliance Compliance with the study product prescription (%) will be assessed daily by recording how much of the study product was prescribed compared to the amount administered. Baseline to end of intervention (7-28 days) and end of follow-up (12 months)
Secondary Dietary intake A 24-h dietary recall will be conducted to record all food, drink and nutritional feeds taken in the 24 hours prior for analysis of of nutritional intake (i.e., total energy and macro- and micronutrients). Baseline to end of intervention (7-28 days) and end of follow-up (12 months)
Secondary Anthropometry Body weight (kg) will be measured using standard methods to the nearest 0.1kg using a weighing scale without heavy clothing. Height will be measured at baseline only using standard measures to the nearest 0.1cm, without shoes or socks. . Height and weight measures will be used to calculate body mass index (BMI). Baseline to end of intervention (7-28 days) and end of follow-up (12 months)
Secondary Dietetic goal A dietetic goal (e.g., weight increase/maintenance, improved/maintained GI tolerance, improved/maintained compliance) will be set by the investigating dietitian at baseline (Day 1) for each patient. At the end of the intervention period, the investigating dietitian will assess and note if the dietetic goal was met. Baseline to end of intervention (7-28 days) and end of follow-up (12 months)
Secondary Safety (Adverse events) Adverse events will be recorded throughout the study Baseline to end of intervention (7-28 days) and end of follow-up (12 months)
Secondary Calf circumference Calf circumference (of the dominant leg) will be measured using standard measures to the nearest 0.1cm using a measuring tape 6-months to 12-months follow-up
Secondary Handgrip strength Dominant handgrip strength (kg) will be assessed using a handgrip dynamometer 6-months to 12-months follow-up
Secondary 30-s Chair Stand Test Number of times patients can stand up and sit down from a chair as many times as possible within 30 seconds. 6-months to 12-months follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients